Erschienen in:
01.04.2005 | For debate
The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
verfasst von:
M. A. Nauck, A. El-Ouaghlidi
Erschienen in:
Diabetologia
|
Ausgabe 4/2005
Einloggen, um Zugang zu erhalten
Excerpt
Glucagon-like peptide 1 (GLP-1) and its derivatives have generated considerable interest [
1]. GLP-1 has the potential to normalise glucose concentrations in patients with type 2 diabetes; however, this peptide hormone is degraded and eliminated from the circulation too rapidly to be of therapeutic value. The initial step of proteolytic cleavage and inactivation is mediated by dipeptidyl peptidase-IV (DPP-IV), following which, only 10–15% of the peptide remains in its intact, biologically active form during the continuous infusion of GLP-1 [
2]. DPP-IV inhibitors reverse this effect, increasing circulating levels by a factor of 4–6 during the infusion of exogenous GLP-1 [
3], thus providing the rationale for their use in diabetes therapy. Phase II studies have shown that DPP-IV inhibitors can lower HbA
1c levels by approximately 1%, thus confirming their therapeutic potential [
4]. …